|
|
Vaccine Detail
|
GVAX Leukemia Vaccine |
| Vaccine Information |
- Vaccine Name: GVAX Leukemia Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: subcutaneous/intradermal injection
- Description: The vaccine uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. (Ho et al., 2022) The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer. (NCT01773395)
|
| Host Response |
|
|
| References |
Ho et al., 2022: Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood advances. 2022; 6(7); 2183-2194. [PubMed: 34807983].
NCT01773395: GVAX vs. Placebo for MDS/AML After Allo HSCT [https://clinicaltrials.gov/study/NCT01773395]
|
|
